Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.30
-0.04 (-0.54%)
Oct 21, 2025, 2:50 PM EDT - Market open
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $26.77M in the quarter ending June 30, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $102.19M, down -8.42% year-over-year. In the year 2024, Gyre Therapeutics had annual revenue of $105.76M, down -6.78%.
Revenue (ttm)
$102.19M
Revenue Growth
-8.42%
P/S Ratio
7.06
Revenue / Employee
$176,492
Employees
579
Market Cap
753.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
Dec 31, 2022 | 102.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 6 days ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 7 days ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 2 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire